Search

Your search keyword '"Barta, Stefan"' showing total 160 results
Start Over Author "Barta, Stefan" Search Limiters Peer Reviewed
160 results on '"Barta, Stefan"'

1. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study

Author

Grover, Natalie S., Annunzio, Kaitlin, Watkins, Marcus, Torka, Pallawi, Karmali, Reem, Anampa-Guzmán, Andrea, Oh, Timothy S., Reves, Heather, Tavakkoli, Montreh, Hansinger, Emily, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Shouse, Geoffrey, Olszewski, Adam J., and Epperla, Narendranath

Published
2024
Full Text
View/download PDF

2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

Author

Ghilardi, Guido, Fraietta, Joseph A., Gerson, James N., Van Deerlin, Vivianna M., Morrissette, Jennifer J. D., Caponetti, Gabriel C., Paruzzo, Luca, Harris, Jaryse C., Chong, Elise A., Susanibar Adaniya, Sandra P., Svoboda, Jakub, Nasta, Sunita D., Ugwuanyi, Ositadimma H., Landsburg, Daniel J., Fardella, Eugenio, Waxman, Adam J., Chong, Emeline R., Patel, Vrutti, Pajarillo, Raymone, Kulikovskaya, Irina, Lieberman, David B., Cohen, Adam D., Levine, Bruce L., Stadtmauer, Edward A., Frey, Noelle V., Vogl, Dan T., Hexner, Elizabeth O., Barta, Stefan K., Porter, David L., Garfall, Alfred L., Schuster, Stephen J., June, Carl H., and Ruella, Marco

Published
2024
Full Text
View/download PDF

6. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

Author

Zinzani, Pier Luigi, Izutsu, Koji, Mehta-Shah, Neha, Barta, Stefan K, Ishitsuka, Kenji, Córdoba, Raul, Kusumoto, Shigeru, Bachy, Emmanuel, Cwynarski, Kate, Gritti, Giuseppe, Prica, Anca, Jacobsen, Eric, Feldman, Tatyana, Guillermin, Yann, Ennishi, Daisuke, Yoon, Dok Hyun, Domenech, Eva Domingo, Zain, Jasmine, Wang, Jie, Kim, Jin Seok, Poel, Marjolein van der, Jin, Jin, Wu, Sutan, Chen, Yang, Moriyama, Takaya, Inoue, Ai, Nakajima, Keiko, and Horwitz, Steven M

Published
2024
Full Text
View/download PDF

7. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Author

Epperla, Narendranath, Huang, Ying, Cashen, Amanda F., Vaughn, John L., Hanel, Walter, Badar, Talha, Barta, Stefan K., Caimi, Paolo F., Sethi, Tarsheen K., Reddy, Nishitha, Karmali, Reem, Bello, Celeste, Chavez, Julio C., Kothari, Shalin K., Hernandez-Ilizaliturri, Francisco J., Svoboda, Jakub, Lansigan, Frederick, Glenn, Martha J., Cohen, Jonathon B., Sorge, Caryn, Christian, Beth, Herrera, Alex F., Hamadani, Mehdi, Costa, Luciano J., and Xavier, Ana C.

Published
2024
Full Text
View/download PDF

8. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Author

Goyal, Amrita, O'Leary, Daniel, Dabaja, Bouthaina, Weng, Wen-Kai, Zain, Jasmine, Cutler, Corey, Guitart, Joan, Kim, Youn H., Geskin, Larisa J., Hoppe, Richard T., Wilson, Lynn D., Beaven, Anne W., Horwitz, Steve, Allen, Pamela B., Barta, Stefan K., Bohjanen, Kimberly, Brammer, Jonathan E., Carter, Joi B., Comfere, Nneka, DeSimone, Jennifer A., Dusenbery, Kathryn, Duvic, Madeleine, Huen, Auris, Jagadeesh, Deepa, Kelsey, Chris R., Khodadoust, Michael S., Lechowicz, Mary Jo, Mehta-Shah, Neha, Moskowitz, Alison J., Olsen, Elise A., Poh, Christina, Pro, Barbara, Querfeld, Christiane, Sauter, Craig, Sokol, Lubomir, Sokumbi, Olayemi, Wilcox, Ryan A., Zic, John A., Hamadani, Mehdi, and Foss, Francine

Published
2024
Full Text
View/download PDF

9. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Author

Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, and Barta, Stefan K.

Published
2024
Full Text
View/download PDF

10. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

Author

Karmali, Reem, Machhi, Rushad, Epperla, Narendranath, Shouse, Geoffrey, Romancik, Jason, Moyo, Tamara K., Kenkre, Vaishalee, Ollila, Thomas A., Fitzgerald, Lindsey, Hess, Brian, David, Kevin, Roy, Ishan, Zurko, Joanna, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Ferdman, Robert, Bhansali, Rahul S., Harris, Elyse I., Liu, Jieqi, Nizamuddin, Imran, Ma, Shuo, Moreira, Jonathan, Winter, Jane, Pro, Barbara, Stephens, Deborah M., Danilov, Alexey, Shah, Nirav N., Cohen, Jonathon B., Barta, Stefan K., Torka, Pallawi, and Gordon, Leo I.

Published
2024
Full Text
View/download PDF

11. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

Author

Ghilardi, Guido, Paruzzo, Luca, Svoboda, Jakub, Chong, Elise A., Shestov, Alexander A., Chen, Linhui, Cohen, Ivan J., Gabrielli, Giulia, Nasta, Sunita D., Porazzi, Patrizia, Landsburg, Daniel J., Gerson, James N., Carter, Jordan, Barta, Stefan K., Yelton, Rebecca, Pajarillo, Raymone, Patel, Vrutti, White, Griffin, Ballard, Hatcher J., Weber, Elizabeth, Napier, Ellen, Chong, Emeline R., Fraietta, Joseph A., Garfall, Alfred L., Porter, David L., Milone, Michael C., O’Connor, Roderick, Schuster, Stephen J., and Ruella, Marco

Published
2024
Full Text
View/download PDF

14. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

16. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Author

Bowers, Jackson T., Anna, Jacob, Bair, Steven M., Annunzio, Kaitlin, Epperla, Narendranath, Pullukkara, Jerrin Joy, Gaballa, Sameh, Spinner, Michael A., Li, Shuning, Messmer, Marcus R., Nguyen, Joseph, Ayers, Emily C., Wagner, Charlotte B., Hu, Boyu, Di, Mengyang, Huntington, Scott F., Furqan, Fateeha, Shah, Nirav N., Chen, Christina, Ballard, Hatcher J., Hughes, Mitchell E., Chong, Elise A., Nasta, Sunita D., Barta, Stefan K., Landsburg, Daniel J., and Svoboda, Jakub

Published
2023
Full Text
View/download PDF

17. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Karmali, Reem, Torka, Pallawi, Shea, Lauren, Oh, Timothy S., Anampa-Guzmán, Andrea, Reves, Heather, Tavakkoli, Montreh, Greenwell, Irl Brian, Hansinger, Emily, Umyarova, Elvira, Annunzio, Kaitlin, Sawalha, Yazeed, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Grover, Natalie S., and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

19. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells

Author

Landsburg, Daniel J., Nasta, Sunita D., Svoboda, Jakub, Gerson, James N., Schuster, Stephen J., Barta, Stefan K., Chong, Elise A., Difilippo, Heather, Weber, Elizabeth, Cunningham, Kathleen, Catania, Christopher, Garfall, Alfred L., Stadtmauer, Edward A., Frey, Noelle V., and Porter, David L.

Published
2023
Full Text
View/download PDF

20. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Author

Barta, Stefan K., Hamdan, Ayad, Boué, François, Delobel, Pierre, Galicier, Lionel, Coppo, Paul, Ghesquières, Hervé, Rubinstein, Paul G, Moore, Page C, Bimali, Milan, Lee, Jeanette Y, Rudek, Michelle A, Chadburn, Amy, Ratner, Lee, Henry, David H, Cesarman, Ethel, DeMarco, Camille E, Costagliola, Dominique, Taoufik, Yassine, Ramos, Juan Carlos, Sharon, Elad, Reid, Erin G, Ambinder, Richard F, Mitsuyasu, Ronald, Mounier, Nicolas, Besson, Caroline, and Noy, Ariela

Published
2023
Full Text
View/download PDF

21. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Author

Zurko, Joanna, Nizamuddin, Imran, Epperla, Narendranath, David, Kevin, Cohen, Jonathon B., Moyo, Tamara K., Ollila, Thomas, Hess, Brian, Roy, Ishan, Ferdman, Robert, Liu, Jieqi, Chowdhury, Sayan Mullick, Romancik, Jason, Bhansali, Rahul S., Harris, Elyse I., Sorrell, Mckenzie, Masel, Rebecca, Kittai, Adam S., Denlinger, Nathan, Sigmund, Audrey M., Fitzgerald, Lindsey, Galvez, Carlos, Ma, Shuo, Winter, Jane, Pro, Barbara, Gordon, Leo I., Danilov, Alexey, Stephens, Deborah, Shah, Nirav N., Kenkre, Vaishalee, Barta, Stefan K., Torka, Pallawi, Shouse, Geoffrey, and Karmali, Reem

Published
2023
Full Text
View/download PDF

22. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

24. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Author

Thomas, Nicole, Dreval, Kostiantyn, Gerhard, Daniela S., Hilton, Laura K., Abramson, Jeremy S., Ambinder, Richard F., Barta, Stefan, Bartlett, Nancy L., Bethony, Jeffrey, Bhatia, Kishor, Bowen, Jay, Bryan, Anthony C., Cesarman, Ethel, Casper, Corey, Chadburn, Amy, Cruz, Manuela, Dittmer, Dirk P., Dyer, Maureen A., Farinha, Pedro, Gastier-Foster, Julie M., Gerrie, Alina S., Grande, Bruno M., Greiner, Timothy, Griner, Nicholas B., Gross, Thomas G., Harris, Nancy L., Irvin, John D., Jaffe, Elaine S., Henry, David, Huppi, Rebecca, Leal, Fabio E., Lee, Michael S., Martin, Jean Paul, Martin, Marie-Reine, Mbulaiteye, Sam M., Mitsuyasu, Ronald, Morris, Vivian, Mullighan, Charles G., Mungall, Andrew J., Mungall, Karen, Mutyaba, Innocent, Nokta, Mostafa, Namirembe, Constance, Noy, Ariela, Ogwang, Martin D., Omoding, Abraham, Orem, Jackson, Ott, German, Petrello, Hilary, Pittaluga, Stefania, Phelan, James D., Ramos, Juan Carlos, Ratner, Lee, Reynolds, Steven J., Rubinstein, Paul G., Sissolak, Gerhard, Slack, Graham, Soudi, Shaghayegh, Swerdlow, Steven H., Traverse-Glehen, Alexandra, Wilson, Wyndham H., Wong, Jasper, Yarchoan, Robert, ZenKlusen, Jean C., Marra, Marco A., Staudt, Louis M., Scott, David W., and Morin, Ryan D.

Published
2023
Full Text
View/download PDF

26. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Author

Bond, David A., Switchenko, Jeffrey M., Villa, Diego, Maddocks, Kami, Churnetski, Michael, Gerrie, Alina S., Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Hill, Brian T., Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max, Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I., Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S., Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Blum, Kristie A., and Cohen, Jonathon B.

Published
2021
Full Text
View/download PDF

29. Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

Author

Elghawy, Omar, Cao, Miao, Xu, Jason, Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Chong, Elise A., Schuster, Stephen J., Thomas, Colin J., Carter, Jordan S., Tavakkoli, Montreh, Ruella, Marco, and Barta, Stefan K.

Subjects
T-cell lymphoma, FLOW cytometry, BONE marrow, TUMOR markers, DISEASE prevalence, AGE distribution, FUNCTIONAL status, RETROSPECTIVE studies, MULTIVARIATE analysis, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, ANTIGENS, IMMUNOHISTOCHEMISTRY, GENE expression, STATISTICS, SURVIVAL analysis (Biometry), DATA analysis software, T helper cells
Abstract

Simple Summary: T-cell lymphomas are hematologic cancers that are difficult to manage due to their aggressive nature and poor response to traditional chemotherapies. Response rates are unpredictable even in the era of novel therapeutics, and there has yet to be a clinically validated cellular marker associated with response rates or treatment outcomes. CD5 is a cellular marker that has been associated with poor outcomes in other cancers but has not been well established in T-cell lymphoma. This study confirmed that CD5 has a high prevalence in T-cell lymphomas and is associated with poor prognostic markers such as advanced age, bone marrow involvement, and poor functional status. Additionally, CD5 was associated with inferior survival in T-follicular cell lymphoma and adult T-cell lymphoma. These results suggest that CD5 is associated with worse prognosis in T-cell lymphomas and may be a potential therapeutic target in future studies. Background: T-cell lymphomas (TCLs) are a group of heterogenous cancers with poor rates and duration of response. There remains a great challenge in risk stratification of these cancers. Cluster of differentiation (CD) 5 has shown prognostic implication in many subtypes of B-cell lymphoma; however, its role in TCLs is not known. Methods: We performed a single-institution retrospective analysis of newly diagnosed patients with TCL. CD5 positivity was determined based on positive results via immunohistochemistry and/or flow cytometry. We used univariate and multivariable analysis of biological factors to assess their association with survival outcomes. Results: A total of 194 patients with TCL spanning 14 subtypes were identified. CD5 positivity was noted in 63% of patients, with the highest proportion of CD5 expression in TFH TCL (93.9%), PTCL-NOS (82.9%), and ATLL (77.8%) (p = 0.00004). Older age at diagnosis (p = 0.001), stage III or IV disease (p = 0.05), and bone marrow involvement (p = 0.003) were also associated with CD5 expression. Complete response rates were numerically lower in patients with CD5+ TCL across all subtypes. OS/PFS was not statistically associated with CD5 status in the overall cohort; however there was significantly decreased OS in CD5+ TFH TCL (p = 0.04) and CD5+ ATLL (p = 0.04) patients. Conclusions: This study represents the first to examine CD5 expression as a prognostic biomarker for outcomes in TCL. The frequent expression of CD5 in the most common nodal TCL in the Western world underpins its potential as an attractive target for cellular therapies. Confirmation of these findings in a larger cohort and investigation of potential pathophysiological mechanisms explaining our observations are planned. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature.

Author

Silva, Genevieve S., Kim, Ellen J., Barta, Stefan K., and Chung, Jina

Subjects
REGULATORY T cells, DRUG side effects, T-cell lymphoma, LITERATURE reviews, IMMUNE checkpoint inhibitors, CUTANEOUS T-cell lymphoma
Abstract

Mogamulizumab is an anti-C–C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review. This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others. Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Author

Diefenbach, Catherine S, Hong, Fangxin, Ambinder, Richard F, Cohen, Jonathon B, Robertson, Michael J, David, Kevin A, Advani, Ranjana H, Fenske, Timothy S, Barta, Stefan K, Palmisiano, Neil D, Svoboda, Jakub, Morgan, David S, Karmali, Reem, Sharon, Elad, Streicher, Howard, Kahl, Brad S, and Ansell, Stephen M

Published
2020
Full Text
View/download PDF

33. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Author

Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, and Hernandez-Ilizaliturri, Francisco J.

Published
2020
Full Text
View/download PDF

38. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.

Author

Chong, Elise A, Kumashie, Kingsley Gideon, Chong, Emeline R, Fabrizio, Joseph, Gupta, Aditi, Svoboda, Jakub, Barta, Stefan K, Walsh, Kristy M, Napier, Ellen B, Lundberg, Rachel K, Nasta, Sunita D, Gerson, James N, Landsburg, Daniel J, Gonzalez, Joyce, Gaano, Andrew, Weirick, Madison E, McAllister, Christopher M, Awofolaju, Moses, John, Gavin N, and Kammerman, Shane C

Subjects
SARS-CoV-2, T helper cells, VACCINE effectiveness, CHRONIC lymphocytic leukemia, IMMUNOGLOBULIN M
Abstract

Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic messenger RNA vaccine response in retrospective and prospective cohorts with lymphoma and chronic lymphocytic leukemia, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active treatment, but nonresponse was also common within observation and posttreatment groups. Total immunoglobulin A and immunoglobulin M correlated with successful vaccine response. In individuals treated with anti-CD19–directed chimeric antigen receptor–modified T cells, nonresponse was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to individualize vaccine timing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Author

Ryu Tiger, Yun Kyoung, Jain, Salvia, Barta, Stefan K., Tolu, Seda, Estrella, Brian, Sawas, Ahmed, Lue, Jennifer K., Francescone, Mark M., Pro, Barbara, and Amengual, Jennifer E.

Subjects
T-cell lymphoma, HISTONE deacetylase inhibitors, PEMETREXED, FOLIC acid, T cells
Abstract

Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R mature T cell lymphomas (MTCL). Patients received pralatrexate 25 mg/m2 and romidepsin 12 mg/m2 every 2 weeks. Fourteen patients were evaluable for efficacy. Overall response rate was 35.7% with CR in 14.3% and disease control in 50%. The mDOR was 8.2 months, mPFS was 3.6 months, and mOS was 20.2 months. Gastrointestinal side effects were most common in up to 33%; there was only one hematologic toxicity of grade 3 anemia. Combining results of MTCL patients from the Phase I and II studies (N = 28), the ORR was 53.5% with CR in 21.4%, disease control in67.8%, and DOR of 7.2 months. The combination was safe however does not out-perform other combination strategies.Trial Registration: (NCT 01947140). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.

Author

Thomas, Colin J., Carvajal, Veronica, and Barta, Stefan K.

Subjects
THERAPEUTIC use of antineoplastic agents, NF-kappa B, HEMATOPOIETIC stem cell transplantation, RISK assessment, NON-Hodgkin's lymphoma, IMMUNOTHERAPY, TREATMENT effectiveness, CYTOTOXINS, PROTEIN-tyrosine kinases, ALGORITHMS, OVERALL survival
Abstract

Simple Summary: Discussed here is a review of the changing landscape in the treatment of mantle cell lymphoma (MCL) regarding the emergence and use of targeted therapy. Targeted therapy is the use of small molecules designed to interrupt specific mechanisms within the cancer cell to exert anti-tumor efficacy. Targeting such mechanisms relies upon our understanding of what makes a cancer cell malignant. MCL is a difficult-to-treat lymphoid cancer that relies heavily upon constitutive intracellular signaling, promoting its growth and survival. The mainstay of MCL treatment has been to treat it with cytotoxic chemotherapy; however, targeted therapies have allowed for improved treatment outcomes and continue to change the way we manage this disease. This review aims to describe what targeted therapies are being utilized in MCL treatment and their mechanisms of action, safety, and efficacy, as well as future directions for their use in MCL treatment. Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin's lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton's Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.

Author

Ghilardi, Guido, Paruzzo, Luca, Patel, Vrutti, Svoboda, Jakub, Chong, Emeline R., Fardella, Eugenio, Chong, Elise A., Gabrielli, Giulia, Nasta, Sunita D., Landsburg, Daniel J., Carter, Jordan, Pajarillo, Raymone, Barta, Stefan K., White, Griffin, Weber, Elizabeth, Napier, Ellen, Porter, David L., Garfall, Alfred L., Schuster, Stephen J., and Ruella, Marco

Subjects
CHIMERIC antigen receptors, OVERALL survival
Abstract

Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. However, bendamustine as lymphodepletion prior to lisocabtagene maraleucel (liso-cel), a 4-1BB co-stimulated, fixed CD4:CD8 ratio anti-CD19 CART product, has not been described yet. Thus, we studied a cohort of sequentially-treated patients with large B-cell lymphomas who received bendamustine lymphodepletion before liso-cel at the University of Pennsylvania between 5/2021 and 12/2023 (n = 31). Patients were evaluated for toxicities and responses. Of note, 7 patients (22.6%) would have dnot met the inclusion criteria for the registrational liso-cel clinical trials, mostly due to older age. Overall and complete response rates were 76.9% and 73.1%, respectively. At a median follow-up of 6.3 months, the 6-month progression-free and overall survival were 59.9% and 91.1%, respectively. Rates of cytokine-release syndrome (CRS) and neurotoxicity (ICANS) of any grade were 9.7% and 9.7%, respectively, with no grade ≥ 3 events. No infections were reported during the first 30 days following liso-cel infusion. Neutropenia ≥ grade 3 was observed in 29.0% of patients; thrombocytopenia ≥ grade 3 occurred in 9.7%. In conclusion, bendamustine lymphodepletion before liso-cel appears to be a strategy that can drive tumor responses while ensuring a mild toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.

Author

Ghilardi, Guido, Williamson, Staci, Pajarillo, Raymone, Paruzzo, Luca, Chen, Linhui, Grady, Connor, Doucette, Abigail, Nemecek, Eneida, Gabrielli, Giulia, Barta, Stefan K., Svoboda, Jakub, Chong, Elise A., Yelton, Rebecca, Nasta, Sunita D., Landsburg, Daniel J., Ugwuanyi, Ositadimma, Chen, Andy I., Schachter, Levanto, White, Griffin, and Ballard, Hatcher J.

Subjects
CANCER treatment, T cells, HEALTH service areas, IMMUNOTHERAPY, SOCIOECONOMIC factors, TREATMENT effectiveness, DISEASE prevalence, POPULATION geography, DESCRIPTIVE statistics, TERTIARY care, LONGITUDINAL method, MINORITIES, B cell lymphoma, CELL receptors, SPECIALTY hospitals
Abstract

Background: Administration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset of non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care centers. We investigated whether minority health populations (MHPs) have equal access to CART19 and whether their outcomes are similar to those of non-MHPs. Methods: We analyzed the prevalence and clinical outcomes of patients treated with commercial CART19 at two geographically and socioeconomically different institutions: the Abramson Cancer Center (ACC, Philadelphia, Pennsylvania) and the Knight Cancer Institute (KCI, Portland, Oregon). Results: In the ACC catchment area, 8956 patients were diagnosed with NHL between 2015 and 2019 (latest available data from the state registry), including 17.9% MHPs. In the ACC, between 2018 and 2022 (CART became available in 2018), 1492 patients with LBCL were treated, and 194 received CART19. The proportion of MHPs was 15.7% for the entire LBCL cohort but only 6.7% for the CART19 cohort. During the same time, in the KCI catchment area, 4568 patients were diagnosed with NHL, including 4.2% MHPs. In the KCI, 396 patients with LBCL were treated, and 47 received CART19. The proportion of MHPs was 6.6% for the entire LBCL cohort and 4.2% for the CART19 cohort. The 3-month response, survival, and toxicities after CART19 infusion showed similar results, although the number of patients who were treated was limited. Conclusions: This study shows that the access of MHPs to tertiary centers for LBCL care was preserved but appeared reduced for commercial CART19 immunotherapy. Although clinical outcomes of MHPs seemed similar to those of non-MHPs, the small sample size precludes drawing firm conclusions. Further studies are needed. (Funded by the Laffey McHugh Foundation and others.) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma.

Author

Weiner, David M., Rastogi, Supriya, Lewis, Daniel J., Cohen, Leah, Choi, Sara, Vittorio, Carmela C., Haun, Paul L., Samimi, Sara S., Villasenor-Park, Jennifer, Bhansali, Rahul S., Chong, Elise A., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Kim, Ellen J., Rook, Alain H., and Barta, Stefan K.

Subjects
INTERFERONS, RETINOIDS, CHEMOKINE receptors, PROGRESSION-free survival, MONOCLONAL antibodies, CUTANEOUS T-cell lymphoma
Abstract

Mogamulizumab is a novel monoclonal antibody designed to target CC chemokine receptor 4 (CCR4), which is expressed by tumor cells in cutaneous T-cell lymphoma (CTCL). In clinical trials, mogamulizumab monotherapy has demonstrated efficacy in reducing tumor burden in advanced CTCL, particularly in the peripheral blood. In clinical practice at our center, mogamulizumab has been combined with other agents such as systemic interferon, systemic retinoids, and extracorporeal photopheresis for an enhanced synergistic effect. There is limited published research on mogamulizumab combination therapy. This study evaluates the clinical efficacy of mogamulizumab in combination with systemic interferon, retinoids, and/or extracorporeal photopheresis for therapy of CTCL. Nineteen patients on this regimen at our academic center were identified. Treatment response rates, progression-free survival, duration of response, and adverse effects were characterized by retrospective chart review. All patients on this regimen at our center had an initial partial or complete response. Moreover, responses were durable, and the regimen was well-tolerated with few grade 3 adverse effects. These results demonstrate the utility of a multimodality approach to the therapy of CTCL with mogamulizumab and warrant further confirmation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Central Nervous System Relapse in T and NK cell Lymphomas.

Author

Taranto, Eleanor P., Barta, Stefan K., and Bhansali, Rahul S.

Abstract

Purpose of Review: T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high rates of mortality. Central nervous system relapse carries significant morbidity, though management is largely extrapolated from literature in B cell neoplasms. As such, outcomes for central nervous system involvement in T/NK cell lymphomas are dismal with no standard of care. In this review, we discuss the epidemiology of central nervous system relapse in T/NK cell lymphomas and critically analyze available literature regarding prophylaxis and treatment. Recent Findings: Retrospective studies of central nervous system involvement in T/NK cell lymphomas have been limited by small sample sizes and heterogeneity of subtypes, though sites of extranodal involvement and disease subtypes are consistently reported as risk factors. Compelling evidence for the use of central nervous system–directed prophylactic therapy has not yet been established, though recent reports of central nervous system activity with novel agents may suggest promising therapeutic options. Summary: The overall rarity of T and NK cell lymphomas has precluded adequate study of prophylaxis and treatment of central nervous system relapse. Collaborative efforts are needed to better define strategies to address CNS disease in T/NK cell lymphomas. These should involve the use of targeted agents, which may hold an advantage over traditional cytotoxic drugs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Author

Petrich, Adam M., Gandhi, Mitul, Jovanovic, Borko, Castillo, Jorge J., Rajguru, Saurabh, Yang, David T., Shah, Khushboo A., Whyman, Jeremy D., Lansigan, Frederick, Hernandez-Ilizaliturri, Francisco J., Lee, Lisa X., Barta, Stefan K., Melinamani, Shruthi, Karmali, Reem, Adeimy, Camille, Smith, Scott, Dalal, Neil, Nabhan, Chadi, Peace, David, Vose, Julie, Evens, Andrew M., Shah, Namrata, Fenske, Timothy S., Zelenetz, Andrew D., Landsburg, Daniel J., Howlett, Christina, Mato, Anthony, Jaglal, Michael, Chavez, Julio C., Tsai, Judy P., Reddy, Nishitha, Li, Shaoying, Handler, Caitlin, Flowers, Christopher R., Cohen, Jonathon B., Blum, Kristie A., Song, Kevin, Sun, Haowei (Linda), Press, Oliver, Cassaday, Ryan, Jaso, Jesse, Medeiros, L. Jeffrey, Sohani, Aliyah R., and Abramson, Jeremy S.

Published
2014
Full Text
View/download PDF

50. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.

Author

Epperla, Narendranath, Feng, Lei, Shah, Nirav N., Fitzgerald, Lindsey, Shah, Harsh, Stephens, Deborah M., Lee, Catherine J., Ollila, Thomas, Shouse, Geoffrey, Danilov, Alexey V., David, Kevin A., Torka, Pallawi, Hashmi, Hamza, Hess, Brian, Barta, Stefan K., Romancik, Jason T., Cohen, Jonathon B., Annunzio, Kaitlin, Kittai, Adam S., and Reneau, John

Subjects
CENTRAL nervous system, CYTOKINE release syndrome, T cells, CENTRAL nervous system diseases, PATIENT experience
Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performed a multicenter retrospective cohort study to evaluate the outcomes of patients with secondary CNS lymphoma (SCNSL) who received CAR-T. Eligibility required active CNSL at the time of apheresis. The objectives included evaluation of overall survival (OS), progression-free survival (PFS), identification of predictors of complete response (CR) post-CAR-T, and assessment of risk factors for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Sixty-one patients were included in the analysis. The overall response rate was 68% with a CR rate of 57%. In the multivariable analysis, patients who experienced any grade CRS had higher odds of achieving CR (OR = 3.9, 95% CI = 1.01–15.39, p = 0.047). The median PFS was 3.3 months (95% CI = 2.6–6.0 months) with 6- and 12-month PFS rates of 35% and 16%, respectively. The median OS was 7.6 months (95% CI = 5.0–13.5 months) with 6- and 12-month OS rates of 59% and 41%, respectively. Any grade CRS and ICANS were 70% (n = 43) and 57% (n = 34), respectively with grade ≥ 3 CRS and ICANS rates of 16% and 44%. Factors associated with increased risk of CRS and ICANS included receiving axi-cel or having leptomeningeal ± parenchymal + CNS involvement, respectively. Despite achieving high response rates, most patients experience early relapse or death following CAR-T in SCNSL. The current study provides a benchmark for future trials exploring novel therapeutic options in SCNSL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results